NRX Pharmaceuticals, Inc.: insider trades · United States · SEC (Form 4)

About NRX Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. is a U.S.-based clinical-stage biopharmaceutical company listed on the NASDAQ market under ticker NRXPW. Headquartered in Wilmington, Delaware, United States, the company is focused on severe psychiatric and central nervous system disorders with significant unmet medical need. Its business model is built around clinical development, regulatory execution, and eventual commercialization of therapies aimed at patients with severe depression, bipolar depression with suicidal ideation, PTSD, and related neuropsychiatric conditions. NRx was founded around the premise of repurposing known molecules for high-value, high-need indications rather than relying solely on de novo drug discovery. That positioning has shaped the company into a specialist in interventional psychiatry. Its core programs center on NRX-100, a preservative-free intravenous ketamine product, and NRX-101, an oral combination therapy being developed for bipolar depression in patients with suicidal ideation and behavior. The company also references broader development efforts in PTSD and other severe mental health disorders. From a competitive standpoint, NRx remains a small-cap, development-stage company, which means it carries materially higher execution and regulatory risk than large-cap pharmaceutical peers. Its potential strategic advantage lies in its narrow therapeutic focus, the use of known pharmacology, and the targeting of clinically urgent patient segments where treatment options remain limited. Management has pursued multiple regulatory paths, including both ANDA and NDA strategies, to broaden the probability of eventual approval and commercialization. In parallel with its drug pipeline, NRx has launched HOPE Therapeutics, a subsidiary aimed at delivering integrated psychiatric care. That platform combines neuroplastic medications, transcranial magnetic stimulation (TMS), hyperbaric oxygen therapy, digital therapeutics, and medication management. This services-based layer could help the company build closer links with patients and prescribing physicians while creating a complementary commercial channel alongside its pharmaceutical pipeline. Recent company developments are highly relevant for investors. During 2025 and into early 2026, NRx reported regulatory progress with the FDA on NRX-100, including Fast Track designation and discussions intended to identify a path toward broader approval. The company also said it had refiled an ANDA for preservative-free ketamine and was targeting an NDA filing around June 2026. For French-speaking investors, NRx should therefore be viewed as a speculative NASDAQ-listed U.S. healthcare name with a strong regulatory catalyst profile and meaningful dependence on FDA outcomes.